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Introduction
Sepsis is a major complication of  severe burn and is one 
of  the principal causes of  death in burned patients. As 
an initial factor, sepsis and multiple organ dysfunction 
syndrome (MODS) caused by sepsis are the principal 
causes of  death in burned patients. Despite the impressive 
advances in our understanding of  the basic mechanisms 
of  sepsis, the mortality rates in burned patients that are 
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A B S T R A C T
As an initial factor, sepsis and multiple organ dysfunction syndrome (MODS) caused by sepsis are the principal causes of death in burned 
patients. In this report, we measured the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-8 in severely burned patients 
with sepsis after the initiation of continuous vein-vein hemodiafi ltration (CVVHDF) to evaluate the clinical usefulness of CVVHDF on the 
removal of key mediators. The vital sign indices, such as the heart rate (HR), respiration (R) and central venous pressure (CVP), were 
recorded at 0 and 42 h in each group. Further, the laboratory examinations indexes, such as the white blood cell count, blood sugar, se-
rum sodium, blood urea nitrogen and serum creatinine, were detected in venous blood samples. Twenty-two severely burned patients 
suﬀ ering from sepsis were randomized into the control group (A, n = 11) and the experimental group (B, n = 11). The patients in group A 
underwent conventional treatment, and those in group B received conventional+CVVHDF treatment. The vital signs, such as the HR, R, 
and CVP, and laboratory examination indices, such as the blood cell count, blood sugar, serum sodium, blood urea nitrogen, and serum 
creatinine, dropped signifi cantly in group B compared with those in group A at 42 h (P < 0.05). The plasma levels of TNF-α, IL-6 and IL-8 
were measured at 0, 12, 18, 24, 36 and 42 h after the start of CVVHDF and at the same time points after the patients were diagnosed 
with sepsis in group A. The plasma levels of TNF-α in group B decreased by 32% at 18 h after the start of CVVHDF and decreased by 43% 
at 42 h after the start of CVVHDF; however, these levels were increased compared with the normal values (P < 0.01). The plasma levels 
of IL-6 decreased at 18 h after the start of CVVHDF (0.274 ± 0.137 ng/ml). Following a brief increase at 24 h, the plasma levels of IL-6 
again decreased continuously until the end of the investigation (0.192 ± 0.119 ng/ml). The plasma levels of IL-8 in group B decreased by 
56% at 18 h after the start of CVVHDF, but they were increased compared with the normal values (P < 0.01). The plasma levels of IL-8 in 
group B decreased by 70% at 42 h after the start of CVVHDF, but they were increased compared with the normal values (P < 0.01). The 
MODS incident was 4 of 11 in group A compared with 1 of 11 in group B (P < 0.01). In conclusion, CVVHDF can eﬀ ectively reduce the levels 
of TNF-α, IL-6 and IL-8 as well as the MODS incidence in patients with serious burns.
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associated with sepsis remain high. In 1992, sepsis was 
considered a systemic inflammatory response syndrome 
(SIRS) that is caused by a serious infection[1], and this 
definition of  sepsis is still used today. The foundation of  
the clinical pathophysiology of  sepsis is SIRS while the 
etiology resulting in SIRS with the sepsis status is infec-
tion.[2] Sepsis due to bacterial infection or SIRS due to 
non-infectious causes, such as trauma like burns, develops 
in part from the release of  many biologically active inflam-
matory mediators. Great importance has been attached 
to the study of  treating sepsis after burns worldwide. 
Continuous vein-vein hemodiafiltration (CVVHDF) can 
effectively eliminate the endogenous and exogenous toxins 
and regulate homeostasis. Thus, CVVHDF can become 
an effective treatment option for sepsis. From June 2003 
to October 2012, burned patients with sepsis were treated 
with optimized CVVHDF in our working unit, and good 
clinical effects have been achieved.
Objective and methods
General data
Twenty-two severely burned patients with sepsis, including 
19 males and 3 females, ranging in age from 19 to 46 years, 
were recruited in this study. These 22 patients included 
flame burn (n = 16), chemical burn (n = 3), and hydro-
thermal burn (n = 3) patients. Twenty-two patients were 
randomized into group A (n = 11) and group B (n = 11). 
Patients in group A received conventional treatment, and 
patients in group B received conventional + CVVHDF 
treatment. They all were from the burn centre in the Second 
People Hospital, Shenzhen, Guangdong, China from June 
2003 to October 2012. The criteria for diagnosing sepsis 
and MODS were based on the clinical and laboratory 
findings.[3,4] The diagnosis of  sepsis was based on evidence 
aetiology or cases that were highly suspected to have infec-
tion; additionally, patients who conformed to the any 2 of  
the first 4 items of  the following list plus any single part of  
item 5 were diagnosed as having sepsis:
1. Temperature > 39.0°C or < 35.5°C, continuous 3 d;
2. Heart rate > 120 beats per minute;
3. WBC > 12.0 × 109/l or < 4.0 × 109/l, including 
neutrophils > 80%;
4. Breathing rate > 28 times/min; and
5. Clinical burn symptoms such as depression, irritability 
or delirious speech; abdominal distension, diarrhea or 
gastrointestinal bleeding; and tongue color changes, 
burr, dry and without saliva.
Informed consent was obtained from the patients or their 
family members according to the guidelines of  the Ethics 
Committee.
Protocol
Subjects in the experimental group were treated with CV-
VHDF using the Prisma system (BRAUN Diapact, Japan); a 
dual lumen central venous catheter (17 cm BRAUN Haemocat 
Signo, USA) was usually inserted in non-burned areas, most 
commonly into the femoral vein, or rarely into the external 
jugular veins. The CVVHDF was conducted near the bed; the 
displacement liquid was Port formula, and the blood flow rate 
was maintained at between 80 and 100 ml/min. The displace-
ment fluid was infused pre-dilution at a rate varying between 
1,500 and 2,000 ml/h, and each treatment lasted 12 h.
Measurements
Venous blood samples were drawn into pyrogen-free heparin-
ized blood specimen tubes at 0, 12, 18, 24, 36 and 42 h after 
CVVHDF initiation in group B and after the patients were 
diagnosed with sepsis in group A. They were immediately 
centrifuged at 3,000 rpm (the centrifugal radius was 13.5 
centimetres) for 15 min, and plasma was obtained and stored 
at –20°C until the mediator assays were performed. Samples 
(0.5 ml) of  ultrafiltrate were collected in pyrogen-free vials at 
0, 12, 18, 24, 36 and 42 h after CVVHDF initiation and frozen 
at –20°C until the assay. According to the manufacturer’s 
instructions, the tumor necrosis factor (TNF)-α, interleukin 
(IL)-6 and IL-8 levels in the plasma and ultrafiltrate were 
detected using an enzyme linked immunosorbent assay 
(the kits were provided by Boster Biological Engineering 
Co., Ltd, Wuhan). The vital sign indices, such as heart rate 
(HR), respiration (R) and central venous pressure (CVP), 
were recorded at 0 and 42 h in each group. The laboratory 
examination indices, such as the white blood cell count, 
blood sugar, serum sodium, blood urea nitrogen and serum 
creatinine, were also detected in the venous blood samples.
Statistical analysis
Measurement data are presented as the mean ± standard 
error (x–   ± s), and the enumeration data are presented as the 
constituent ratio. The statistical analysis of  the measure-
ment data was performed using two-way repeated measures 
analysis of  variance (ANOVA), and that of  the enumeration 
data was performed using the chi-square test with the Statis-
tical Package for the Social Sciences software (SPSS 19.0). 
Differences with P < 0.05 were considered significant.
Results
Patient demographics
The differences in gender, age, total burn surface area 
(TBSA) and burn depth between group A and B were not 
statistically significant (P > 0.05) [Table 1].
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Changes of vital sign indices
Compared with the vital sign indices at 0 h, these indices 
decreased slightly by 42 h in group A. There were no sig-
nificant differences (P > 0.05). However, compared with 
the HR, R and CVP indices at 0 h, these indices obviously 
improved by 42 h in group B (P < 0.05). Compared with 
group A at 42 h, the HR, R and CVP indices in group B 
decreased significantly by 42 h (P < 0.05) [Table 2].
Changes in laboratory examination indices
The laboratory examination indices, including the white 
blood cell count, blood sugar, serum sodium, blood urea 
nitrogen and serum creatinine, at 42 h in group B obviously 
decreased (P < 0.05) compared with these clinical indices at 
0 h. However, in group A at 42 h, the white blood cell count, 
blood sugar, serum sodium, blood urea nitrogen and serum 
creatinine dropped slightly compared with these clinical 
indices at 0 h. This difference had no statistical significance 
(P > 0.05). The laboratory examination indices, including 
the blood cell count, blood sugar, serum sodium, blood 
urea nitrogen, and serum creatinine in group B dropped 
significantly compared with these indices in group A at 42 h; 
this difference is statistically significant (P < 0.05) [Table 3].
Changes in plasma TNF-α
The plasma levels of  TNF-α exhibited no significant differ-
ences between group A (0.625 ± 0.202 ng/ml) and group B 
(0.634 ± 0.193 ng/ml) before the CVVHDF initiation. The 
plasma levels of  TNF-α in group B were decreased by 32% 
at 18 h after the start of  CVVHDF, but they were higher than 
the normal values (P < 0.01). The TNF-α levels in group 
B decreased by 43% at 42 h after the start of  CVVHDF, 
but they were increased compared with the normal values 
(P < 0.01) [Figure 1].
Changes in plasma IL-6
There were no significant differences in the plasma levels of  
IL-6 between group A (0.399 ± 0.126 ng/ml) and group B 
(0.426 ± 0.102 ng/ml) before the initiation of  CVVHDF. 
The plasma levels of  IL-6 in group B decreased at 18 h after 
the start of  CVVHDF (0.274 ± 0.137 ng/ml). Following a 
brief  increase in group B at 24 h (0.309 ± 0.144 ng/ml), the 
plasma levels of  IL-6 again decreased continuously until the 
end of  the investigation (0.192 ± 0.119 ng/ml) [Figure 2].
Changes in plasma IL-8
There were no significant differences in the plasma IL-8 
levels between group A (0.462 ± 0.218 ng/ml) and group B 
(0.455 ± 0.176 ng/ml) before the initiation of  CVVHDF. 
The plasma levels of  IL-8 in group B were decreased by 
56% at 18 h after the start of  CVVHDF, but they were in-
creased compared with the normal values (P < 0.01). The 
plasma levels of  IL-8 in group B were decreased by 70% at 
42 h after the start of  CVVHDF, but they were increased 
compared with the normal values (P < 0.01). There were 
significant differences in the changes in the plasma IL-8 
levels between the groups during the study interval (P < 
0.01) [Figure 3].
Outcomes and complications
MODS occurred in 4 of  the 11 patients in group A com-
pared with 1 of  the 11 patients in group B (P < 0.01). No 
differences in the median stay in the ICU or total days in 
the hospital were found between the groups. No differences 
in mortality were found between the groups, although 
there were 2 deaths in group A versus 1 in group B. There 
Table 1: Parameters at the time of admission for both groups






TBSA (%) II° burn (%) III° burn (%)
group A 11 10/1 31.4±11.1 66.71±19.73 36.93±14.82 19.79±8.23
group B 11 9/2 31.1±9.1 60.94±19.26 35.81±20.23 11.45±6.54
P value 1.000 0.932 0.463 0.868 0.394
BSA = burn surface area, TBSA = total burn surface area
Table 2: Changes in the vital signs for both groups ( x–  ±s)








group A 11 0 h 155.3±36.2 38.3±13.6 13.7±2.9
42 h 144.1±38.9 32.8±12.4 14.1±5.2
group B 11 0 h 154.6±40.1 34.5±13.6 13.6±4.8
42 h 126.8±35.7ab 25.3±11.2ab 11.3±2.5ab
adenotes the result of the comparison between 0 and 42 h in group B, P < 0.05, 
bdenotes the result of the comparison between groups A and B at the corresponding time 
point, P < 0.05
Table 3: Changes in the laboratory examination indices in both groups ( x–  ±s)
Group Number Time point Na (mmol/L) BUN (mmol/L) Scr (μmol/L) BS (mmol/L) WBC (×109)
group A 11 0 h 143.88±7.09 19.11±3.36 102.46±18.33 12.81±3.04 21.36±3.62
42 h 139.46±5.84 16.23±4.15 96.98±16.91 11.66±1.92 18.64±2.29
group B 11 0 h 144.89±7.36 18.53±3.72 106.85±13.38 13.17±3.85 20.63±3.84
42 h 132.83±6.16ab 12.91±4.47ab 92.06±15.03ab 8.69±2.61ab 10.82±1.37ab
adenotes the result of the comparison between 0 and 42 h in group B, P < 0.05, bdenotes the result of the comparison between groups A and B at the corresponding time point, P < 0.05
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were no heparin-related complications or other CVVHDF-
related complications in any of  the subjects in this study.
Discussion
Due to the early stress response and burn tissue necrosis 
in severe burn patients, the endotoxin that comes from the 
wounds and intestinal tracts causes the release of  inflamma-
tory mediators. Substantial inflammatory mediators would 
cause SIRS, which may be constantly exacerbated through 
the cascade effect and give rise to the “waterfall effect” of  
inflammation[5], which could in turn lead to multiple organ 
injury and, eventually, MODS.
Continuous renal replacement therapy (CRRT) technology 
is a new technology, and it has been widely applied to rescue 
patients with multiple organ failure, which has improved the 
survival rate of  critical cases. CVVHDF is a type of  CRRT 
that was first applied to treat patients with acute renal insuf-
ficiency that is unstable in hemodynamics. According to the 
research, CRRT can eliminate the inflammatory mediator 
in extracorporeal circulation and improve the prognosis of  
sepsis and MODS in animal experiments.[6] Furthermore, 
its effectiveness is related to the treatment strength and 
method.[7] CVVHDF has already been widely applied to 
treat acute severe patients.
In the early stage of  burn sepsis, CVVHDF could improve 
organ function and prevent MODS. Its mechanism may 
be the following:
1. CVVHDF eliminates the inflammatory medium and 
cell factors, such as IL-6, IL-8, IL-1β and TNF-α, to 
interrupt the progress of  SIRS towards MODS and 
MOF; and
2. CVVHDF improves the cardiopulmonary function. 
CVVHDF can eliminate some toxins that could injure 
the cardiopulmonary function, perfect the lung function 
of  gas exchange, correct the volume load and alleviate 
the cardiac preload.
The severity of  multi-organ function injury and case fatal-
ity rate are positively correlated with the plasma levels of  
inflammatory medium[8], and IL-6 is the main member of  
the cytokine network, possibly playing a significant role in 
various infectious diseases. Additionally, it is a marking 
signal that reflects the inflammatory response of  the body. 
Particularly in such pathological states as sepsis and SIRS, 
it can detect increasing IL-6 levels, and its level is closely 
related to the degree of  infection and prognosis.[9] TNF-α 
is an endogenous cell regulatory factor that is generated 
by the activated mononuclear macrophage system; it is 
also the main factor of  immediate inflammatory reactions. 
Currently, TNF-α is thought to come from burn patients’ 
Kupffer cells, which are found in the liver. TNF-α has a 
dual-directional regulation function, and only a small dose 
of  TNF-α can enhance the immunity of  the burn patient. 
A continuous and high level of  TNF-α could hint at a poor 
prognosis of  severe infection.[10,11]
Burn patients with sepsis in our hospital were treated with 
CVVHDF for 12 h, and the blood flow rate was maintained 
at between 80 and 100 ml/min. The treatment lasted for 
Figure 1: Changes in plasma tumor necrosis factor (TNF)-α after 
continous vein-vein hemodiafi ltration (CVVHDF) initiation ‘*’denotes the 
result of the comparison between groups A and B at the corresponding 
time point, P < 0.01.
Figure 2: Changes in plasma interleukin (IL)-6 after continous vein-
vein hemodiafi ltration (CVVHDF) initiation ‘*’denotes the result of the 
comparison between groups A and B at the corresponding time point, 
P < 0.01.
Figure 3: Changes in plasma interleukin (IL)-8 after continous vein-
vein hemodiafi ltration (CVVHDF) initiation ‘*’denotes the result of the 
comparison between groups A and B at the corresponding time point, 
P < 0.01. 
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42 h. According to the research results, CVVHDF can 
effectively reduce the content of  various inflammatory 
factors, thereby decreasing the incidence rate of  MODS. 
Further, CVVHDF treatment can effectively decrease the 
laboratory examination indices, such as the white blood cell 
count, blood sugar, serum sodium, blood urea nitrogen and 
serum creatinine. This can improve the environment in the 
body of  severe burn patients with sepsis. Therefore, CVVH 
treatment is more effective in the primary stage of  sepsis. 
In future research, we will attempt to adopt larger samples 
for further research to obtain more scientific evidence for 
the treatment of  burn sepsis with CVVHDF.
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